996.00
-4(-0.40%)
Currency In GBp
Address
60 Gracechurch Street
London, EC3V 0HR
United Kingdom of Great Britain and Northern Ireland
Phone
44 79 0917 7311
Website
Sector
Healthcare
Industry
Biotechnology
Employees
16
First IPO Date
November 09, 2015
| Name | Title | Pay | Year Born |
| Dr. Vladislav Sandler Ph.D. | Co-Founder, Chief Executive Officer & Director | 445,000 | 1965 |
| Ms. Alexis M. Sandler J.D. | Independent Co-Founder & Non-Executive Director | 60,000 | 1976 |
| Dr. Koen Van Besien M.D., Ph.D. | Clinical Advisor & Medical Director | 0 | N/A |
| Mr. Ben Harber | Company Secretary | 0 | N/A |
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.